Delivery Order SPE2DR25D3005-SPE2DR26FP8DG
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $1,472.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The award, issued on December 1, 2025, with a completion date of December 22, 2025, represents a non-set-aside competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $49,461.72 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This firm fixed-price contract, awarded November 5, 2025, with completion targeted for November 28, 2025, represents a competitively awarded procurement with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $5,888.30 and is scheduled for completion by November 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $14,183.70 to supply 200-unit vials of Xeomin, a botulinum toxin product used for medical purposes. The contract is a firm fixed-price delivery order with an ultimate completion date of November 21, 2025, and was awarded on October 30, 2025, through a non-set-aside competitive procurement. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,352.44 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin injection used for medical and therapeutic purposes. The contract, awarded on November 6, 2025, with an ultimate completion date of December 1, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $11,174.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-set-aside competitive award was issued on September 5, 2025, with an ultimate completion date of September 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP8DGDelivery Order
The Defense Logistics Agency awarded a $2,944.15 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of January 14, 2026, and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The work will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. That master contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies to support military healthcare programs worldwide. The company's extensive portfolio of federal medical procurement demonstrates its established capability as a critical vendor for Defense Health Agency and other federal healthcare systems requiring pharmaceutical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 12/21/25 |